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Available online 7 August 2016Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease causing neural cell degen-
eration and brain atrophy and is considered to be themost common form of dementia.We previously generated
an induced pluripotent stem cell (iPSC) line from anADpatient carrying anA79Vmutation in PSEN1 as an in vitro
disease model. Here we generated a gene-corrected version from this hiPSC line by substituting the point muta-
tionwith thewild-type sequence. The reported A79V-GC-iPSCs line is a very useful resource in combinationwith
the A79V-iPSC line in order to study pathological cellular phenotypes related to this particular mutation.
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The study was approved by the “De Videnskabsetiske Komiteer for
Region Hovedstaden” (protocol number H-4-2011-157), Copenhagen,
Denmark and written informed consent was obtained in all cases. To
protect the patient family privacy, no personal patient information is
presented here. Mutations in presenilin 1 (PSEN1) gene are the most
common known causes of inherited Alzheimer's disease (AD).
A human induced pluripotent stem cell (hiPSC) line was previously
generated from a skin biopsy obtained from a 48-year-old woman car-
rying a heterozygous mutation in exon 4 of the PSEN1 gene, which
causes a change in amino acid A79V. Episomal plasmids carrying gene
sequences for hOCT4, hSOX2, hKLF4, hL-MYC, hLIN28 and a short hairpin
against TP53 (Okita et al., 2011) were used to reprogram the ﬁbroblasts
into iPSCs, successfully establishing integration and feeder-free iPSCs.
This cell line has been described previously as a bona ﬁde iPSC line
with normal karyotype (Li et al., 2016).
The A79V-hiPSC (c.236 C N T) was gene-corrected with the CRISPR/
Cas9 system (Ran et al., 2013) by replacing the point mutation “T”
with the wild-type nucleotide “C” (Fig. 1A). The nucleotide substitu-
tion/correction was validated by sequencing (Fig. 1B). Gene-integrity
was also checked by conﬁrming that the DNA sequence surrounding
the mutation and the CRISPR cutting site were not altered, with no
frameshifts or other mutation(s) being generated upon gene editing,
conﬁrming successful gene correction of A79V-hiPSC, named A79V-
GC-hiPSC (“GC” = gene corrected). The sequencing of the isogenic
line conﬁrmed the c.236 T N C replacement in exon 4 of the PSEN1the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. A. CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC. A) Genomic sequence surrounding the mutation site: mutated nucleotide (T, red); sgRNA recognition
site containing 20 bp (yellow); CRISPR cutting site between the 17th and 18th bp (bold); forward and reverse primers (pink). B) ssODN with 120 bp, 60 bp upstream and 60 bp
downstream the mutation site containing the WT nucleotide (C, green). B. Sequencing of exon 4 of the PSEN1 gene in hiPSCs. A) Heterozygous c.236C N T substitution in the mother
line previously published. B) Successful correction of the point mutation (WT nucleotide – C; Mutated nucleotide – T). C. Immunocytochemical detection in hiPSCs of the pluripotency
markers OCT4, NANOG, SSEA3, SSEA4, TRA1-60 and TRA1-81. Scale bars correspond to 200 μm. D. Representative karyotype of A79V-GC-iPSCs.
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munocytochemical (ICC) analysis of the pluripotency markers OCT4,
NANOG, SSEA3, SSEA4, TRA-1-60 and TRA-1-81 (Fig. 1C) conﬁrmed
the gene-edited line maintained its pluripotency like the mother line
previously published. Finally, karyotyping was performed to conﬁrm
that no chromosomal aberrations were introduced in the isogenic line
upon gene correction (Fig. 1D).
Materials and methods
CRISPR design
Isogenic gene-corrected controls were obtained using the CRISPR/
Cas9 technology in combination with single-stranded oligonucleotides
(ssODNs), which provided the wild-type template for gene-correction.
CRISPRs were designed with the help of the software available at
http://crispr.mit.edu/. The single-guide RNAs (sgRNA) were ordered
from Sigma and the cloning of CRISPRs followed the protocol from
Ran et al. (2013), with a single plasmid containing both the sgRNA
and the Cas9 (pSpCas9(BB)-2A-Puro (PX459) V2.0; addgene ID 48139).
ssODNs were designed to contain 120 bp in total, with 60 bp up-
stream and 60 bp downstream of the cutting site. Screening of clones
was performed with restriction digestions where the wild-type se-
quence was recognized (and cut) by speciﬁc restriction enzymes
(EheI, 5′-GGC↓GCC-3′, ThermoScientiﬁc), while the mutated sequencewas not, which means EheI only digested clones where the ssODN
was successfully integrated.
Nucleofection
A79V-hiPSCs growing on matrigel-coated (Corning Bioscience)
dishes with E8 medium (Gibco) were detached with Accutase (Gibco).
2 × 106 cells were nucleofected with 10 μg of CRISPR/Cas9 plasmid
and 100 pmol of ssODN using the Amaxa 4D Nucleofector (program
CA137, Lonza) and P3 Primary Cell Kit (Lonza) according to the
manufacturer's instructions. Nucleofected hiPSCs were plated back in
a matrigel-coated dish with E8 medium supplemented with 1 mM
ROCK inhibitor (Sigma). hiPSCs were subjected to puromycin selection
4 h after nucleofection and allowed to recover for 4–5 days. Surviving
(resistant) colonies were manually picked into 96 well plates coated
with matrigel with E8 and then expanded for genotyping and
sequencing.
Genotyping and restriction assays
DNA for genotyping was extracted using the prepGem™ Kit
(ZyGEM, PTI0500) (Qiagen). PCR genotyping was performed using
TEMPase Hot Start DNA Polymerase (Ampliqon) according to the
manufacturer's instructions, using an annealing temperature of 60 °C.
The following primers were designed to cover the mutation and
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Table 1
Primary antibodies used for immunocytochemistry.
Antibody and host
species
Dilution Company and catalog
number
Pluripotency Rabbit anti-NANOG 1:500 Peprotech, 500-P236
Goat anti-OCT4 1:500 Santa Cruz, sc-8628
Rat anti-SSEA3 1:100 Biolegend, 330302
Mouse anti-SSEA4 1:100 Biolegend, 330402
Mouse anti-Tra-1-60 1:200 Biolegend, 330602
Mouse anti-Tra-1-81 1:200 Biolegend, 330702
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A79V_Forward2 5′-TCCCAGGTCTAACCGTTACCT-3′ and A79V_Reverse2
5′- ATGCAGAGGCCTTCAAGGTG-3′. PCR products were digested using
the restriction enzyme EheI (ThermoScientiﬁc) according to the
manufacturer's instructions and clones showing correct digestion pat-
ternswere then sequenced to conﬁrm the correction and that no frame-
shifts or other mutations were introduced.
Sequencing
Sanger sequencing of exon 4 of PSEN1 genewas carried out in an ABI
PRISM 310 Genetic Analyzer using a designed set of primers that ﬂank
the mutation site (A79V_Forward2 5′-TCCCAGGTCTAACCGTTACCT-3′
and A79V_Reverse2 5′-ATGCAGAGGCCTTCAAGGTG-3′) according to
standard procedures.
Immunoﬂuorescence staining
hiPSCs were ﬁxed with 4% paraformaldehyde (PFA) in PBS for
15 min and stained by standard immunoﬂuorescence staining proce-
dures. The primary antibodies (Table 1) were visualized with the sec-
ondary antibodies Alexa488 or Alexa594 diluted 1:200 (Life
technologies) and counterstained with Hoechst bisbenzimide 33,258.
Images were acquired with a Leica DMRB-ﬂuorescence microscope
(Leica Microsystems, Wetzlar, Germany).
Karyotyping
A79V-GC-hiPSCs were treated for 45 min with KaryoMAX colcemid
(Life Technologies), harvested in fresh ﬁxative consisting of 25% acetic
acid and 75% methanol and sent for G-band karyotyping (Institute of
Medical Genetics and Applied Genomics, University of Tübingen,
Tübingen, Germany).
Veriﬁcation and authentication
Karyotypingwas performed by Institute ofMedical Genetics andAp-
plied Genomics, University of Tübingen (Tübingen, Germany) and aminimum of 20 metaphases were analyzed. The results showed a nor-
mal 46, XX karyotype, without any detectable abnormalities (Fig. 1D).
A79V-GC-hiPSC line identity and purity was conﬁrmed by sequencing
of PSEN1 (Fig. 1B) and ICC for pluripotency genes expression (Fig. 1C).
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